Zobrazeno 1 - 10
of 90
pro vyhledávání: '"Edward M. Geltman"'
Publikováno v:
Journal of Cardiac Failure. 26:S54
Introduction Mineralocorticoid receptor antagonists (MRAs) have been shown to be beneficial in heart failure (HF). However, there are concerns about hyperkalemia and renal injury for patients (pts) with HF and chronic kidney disease (CKD). Previous t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce0ea3bf5c79e34413c0dcdc55eef043
https://doi.org/10.1016/j.cardfail.2020.09.157
https://doi.org/10.1016/j.cardfail.2020.09.157
Publikováno v:
Transplantation. 98:465-469
BACKGROUND Alcohol cardiomyopathy (ACM) constitutes up to 40% of patients with non-ischemic dilated cardiomyopathy. Transplant-free survival is worse for patients with ACM versus idiopathic dilated cardiomyopathy (IDCM) with continued exposure. The p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::272a7252d89cec7c0628cdbf1ab2bae9
https://doi.org/10.1097/tp.0000000000000083
https://doi.org/10.1097/tp.0000000000000083
Publikováno v:
Journal of Cardiac Failure. 25:S57
Introduction The mineralocorticoid receptor antagonists (MRAs) have been shown to be beneficial in heart failure (HF), improving survival and reducing hospitalizations. The AHA/ACC guidelines now give a Class 1A recommendation to use MRAs in NYHA cla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4224bb2dd75c9c6bd4c1b14ecaeee5c8
https://doi.org/10.1016/j.cardfail.2019.07.160
https://doi.org/10.1016/j.cardfail.2019.07.160
Publikováno v:
The American journal of cardiology. 119(3)
Acute decompensated heart failure (ADHF) is a major reason for repeated hospitalizations. Identifying those patients with ADHF at risk for readmission is critical so that preventive interventions can be implemented. Biomarkers such as B-type natriure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb46b80a73531226125308fd27650d7
https://pubmed.ncbi.nlm.nih.gov/28233534
https://pubmed.ncbi.nlm.nih.gov/28233534
Autor:
Erin R. Foster, Allyson R. Zazulia, M. Tracy Morrison, Dorothy F. Edwards, Edward M. Geltman, Gregory A. Ewald, Kathleen B Cunnane
Publikováno v:
The American Journal of Occupational Therapy. 65:306-313
OBJECTIVE. We investigated participation levels and relationships among cognition, depression, and participation for people with severe congestive heart failure (CHF). METHOD. People with severe CHF (New York Heart Association Class III or IV) awaiti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc641867eb66d49116b50971a3b674e7
https://doi.org/10.5014/ajot.2011.000588
https://doi.org/10.5014/ajot.2011.000588
Publikováno v:
Clinical chemistry. 62(2)
BACKGROUNDGalectin-3 (Gal-3) has been suggested as a prognostic biomarker in heart failure (HF) patients that may better reflect disease progression than traditional markers, including B-type natriuretic peptide (BNP) and cardiac troponins. To fully
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb11b593199b0acb8f6414c99046b73
https://pubmed.ncbi.nlm.nih.gov/26546635
https://pubmed.ncbi.nlm.nih.gov/26546635
Autor:
Anand Rajan, Craig B. Wilen, Mitchell G. Scott, Edward M. Geltman, Jeffrey J. Szymanski, Douglas M. Char, Steven Hung, Paul M. Lavigne
Publikováno v:
Clinical chemistry. 61(6)
BACKGROUND Myocardial infarction is characterized by an increase of cardiac troponin I (cTnI) above the 99th percentile of a reference population. Our hospital switched from 1 contemporary cTnI assay to another and observed a doubling of cTnI results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f918befe7193a0ec350ec0091c284be5
https://pubmed.ncbi.nlm.nih.gov/25886769
https://pubmed.ncbi.nlm.nih.gov/25886769
Autor:
Nader Moazami, Sharon Moorhead, Nirav R. Shah, Edward M. Geltman, Gregory A. Ewald, Michael K. Pasque
Publikováno v:
The Heart Surgery Forum. 9:E823-E827
Background. With recent improvements in medical and device therapy, the benefit of cardiac transplantation for UNOS Status 2 patients has been questioned. No randomized trial has been performed to compare transplantation versus contemporary medical t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c40b7892c1ce0cba6f2316ce3de4eae
https://doi.org/10.1532/hsf98.20061061
https://doi.org/10.1532/hsf98.20061061
Autor:
Sabu Thomas, Edward M. Geltman
Publikováno v:
Congestive Heart Failure. 12:213-218
Doses of angiotensin-converting enzyme (ACE) inhibitors used in the landmark heart failure trials that demonstrated survival benefit are rarely reached in routine practice. The authors review the current literature regarding optimal dosing of ACE inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c384e6172ccfb99fe4477a2b88dac394
https://doi.org/10.1111/j.1527-5299.2006.05367.x
https://doi.org/10.1111/j.1527-5299.2006.05367.x
Autor:
Kenneth B. Schechtman, Joshua M. Stolker, Bastiaan Heere, Linda R. Peterson, Edward M. Geltman
Publikováno v:
The American Journal of Cardiology. 97:1607-1610
In patients with heart failure (HF), peak exercise oxygen consumption (VO2) is an important prognostic tool on which critical clinical decisions are made. However, recent retrospective data have suggested that ventilatory equivalent (VE = ventilation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7a32585bcfb49624fd3479cb5a3f43f
https://doi.org/10.1016/j.amjcard.2005.12.053
https://doi.org/10.1016/j.amjcard.2005.12.053